GIVA cPLA2/PLA2G4A: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of GIVA cPLA2/PLA2G4A. The page also collects GeneMedi's different modalities and formats products for GIVA cPLA2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the GIVA cPLA2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Introcelluar Protein.

This gene encodes a member of the cytosolic phospholipase A2 group IV family. The enzyme catalyzes the hydrolysis of membrane phospholipids to release arachidonic acid which is subsequently metabolized into eicosanoids. Eicosanoids, including prostaglandins and leukotrienes, are lipid-based cellular hormones that regulate hemodynamics, inflammatory responses, and other intracellular pathways. The hydrolysis reaction also produces lysophospholipids that are converted into platelet-activating factor. The enzyme is activated by increased intracellular Ca(2+) levels and phosphorylation, resulting in its translocation from the cytosol and nucleus to perinuclear membrane vesicles. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]

Pre-made anti-GIVA cPLA2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-GIVA cPLA2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-GIVA cPLA2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Recombinant multi-species PA24A/ GIVA cPLA2/ PLA2G4A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine GIVA cPLA2/PLA2G4A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Pre-made PLA2G4A viral vector in GM Promise-ORF^TM

About Promise-ORF^TM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORF^TM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORF^TM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI

If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.